EUVIMEDEUVIMED entdecken
Crossref

GSG2 promotes progression of human endometrial cancer by regulating PD-1/PD-L1 expression via PI3K-AKT pathway

Hong Chen, Shuxi Liu, Sikao Wu, Xianxian Nong, Naiyu Liu, Li Li

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Hong Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, PR China. Electronic address: doctorchen2016@h…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Endometrial Neoplasms, Phosphatidylinositol 3-Kinases, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cell cycle dysregulation leading to uncontrolled growth is a primary characteristic of malignancy. GSG2, a mitosis-related kinase, affects the normal cell cycle by interfering with the normal dissociation of centromere cohesion, and its overexpression has been shown to play an important role in cancer cells. Here, we investigated the function of GSG2 as a tumor promoter in endometrial carcinoma and its relationship with the immunological microenvironment. We used immunohistochemistry to identify a correlation between the development and prognosis of GSG2 and endometrial cancer. Cell and animal experiments confirmed that GSG2 has a protumorigenic phenotype in endometrial cancer cell lines. Furthermore, using GeneChip analysis and a tumor-immune coculture model, we observed a link between GSG2 expression and the composition of the immune microenvironment. Therefore, we concluded that the activation of the PI3K/AKT pathway by GSG2 may impact DNA repair, disrupt the cell cycle, and regulate the immune response, all of which could increase the ability of EC cells to proliferate malignantly. Consequently, it is anticipated that GSG2 will be a viable therapeutic target in endometrial carcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenEndometrial NeoplasmsPhosphatidylinositol 3-KinasesProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins c-aktSignal TransductionAnimalsFemaleHumansMiceAurora Kinase BCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticMice, Inbred BALB CMice, NudeMitogen-Activated Protein Kinase KinasesTumor MicroenvironmentProtein Serine-Threonine KinasesIntracellular Signaling Peptides and Proteins

Stichwörter der Autor:innen

Endometrial cancerGSG2Immune microenvironmentPD-1/PD-L1PI3K/AKT signaling

Substanzen

Aurora Kinase BB7-H1 AntigenMitogen-Activated Protein Kinase KinasesPhosphatidylinositol 3-KinasesProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins c-aktAURKB protein, humanCD274 protein, humanPDCD1 protein, humanPDZ-binding kinase

Autor:innen und Institutionen

  • Department of Gynecology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, PR China. Electronic address: doctorchen2016@hotmail.com.
  • Department of Gynecology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, PR China.
  • Department of Gynecologic Oncology, Guangxi Medical University Affiliated Tumor Hospital, Nanning 530021, PR China. Electronic address: lili@gxmu.edu.cn.

Zitieren

APA

Chen, H., Liu, S., Wu, S., Nong, X., Liu, N., & Li, L. (2024). GSG2 promotes progression of human endometrial cancer by regulating PD-1/PD-L1 expression via PI3K-AKT pathway. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112196

Vancouver

Chen H, Liu S, Wu S, Nong X, Liu N, Li L. GSG2 promotes progression of human endometrial cancer by regulating PD-1/PD-L1 expression via PI3K-AKT pathway. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112196

BibTeX
@article{Chen2024,
  author = {Chen, Hong and Liu, Shuxi and Wu, Sikao and Nong, Xianxian and Liu, Naiyu and Li, Li},
  title = {GSG2 promotes progression of human endometrial cancer by regulating PD-1/PD-L1 expression via PI3K-AKT pathway},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112196}
}
Kostenlos starten →